Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2010 Dec;15(23-24):997-1007. doi: 10.1016/j.drudis.2010.07.007. Epub 2010 Aug 11.

The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform.

Author information

  • 1NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3370, USA.

Abstract

The US Tox21 collaborative program represents a paradigm shift in toxicity testing of chemical compounds from traditional in vivo tests to less expensive and higher throughput in vitro methods to prioritize compounds for further study, identify mechanisms of action and ultimately develop predictive models for adverse health effects in humans. The NIH Chemical Genomics Center (NCGC) is an integral component of the Tox21 collaboration owing to its quantitative high-throughput screening (qHTS) paradigm, in which titration-based screening is used to profile hundreds of thousands of compounds per week. Here, we describe the Tox21 collaboration, qHTS-based compound testing and the various Tox21 screening assays that have been validated and tested at the NCGC to date.

Published by Elsevier Ltd.

PMID:
20708096
[PubMed - indexed for MEDLINE]
PMCID:
PMC2994991
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk